Barclays Maintains an 'Equalweight' on Amylin Pharmaceuticals (AMLN); Solid 4Q, TQT Questions Persist
Tweet Send to a Friend
Barclays maintains an 'Equalweight' on Amylin Pharmaceuticals (NASDAQ: AMLN), PT increased from $12 to $14.
Barclays analyst says, "Overall, 4Q10 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "Overall, 4Q10 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
